Market Cap: $3.2512T -1.790%
Volume(24h): $132.4389B 6.020%
  • Market Cap: $3.2512T -1.790%
  • Volume(24h): $132.4389B 6.020%
  • Fear & Greed Index:
  • Market Cap: $3.2512T -1.790%
Cryptos
Topics
Cryptospedia
News
CryptosTopics
Videos
Top News
Cryptos
Topics
Cryptospedia
News
CryptosTopics
Videos
bitcoin
bitcoin

$106754.608270 USD

1.33%

ethereum
ethereum

$2625.824855 USD

3.80%

tether
tether

$1.000127 USD

-0.03%

xrp
xrp

$2.189133 USD

1.67%

bnb
bnb

$654.521987 USD

0.66%

solana
solana

$156.942801 USD

7.28%

usd-coin
usd-coin

$0.999814 USD

0.00%

dogecoin
dogecoin

$0.178030 USD

1.14%

tron
tron

$0.270605 USD

-0.16%

cardano
cardano

$0.646989 USD

2.77%

hyperliquid
hyperliquid

$44.646685 USD

10.24%

sui
sui

$3.112812 USD

3.86%

bitcoin-cash
bitcoin-cash

$455.764560 USD

3.00%

chainlink
chainlink

$13.685763 USD

4.08%

unus-sed-leo
unus-sed-leo

$9.268163 USD

0.21%

Cryptocurrency News Articles

iotaMotion Announces First Use of its iotaSOFT® Insertion System Outside the United States

May 13, 2025 at 11:14 pm

The technology is in use as a pre-market clinical investigation at University Hospital of Zurich, led by Professor Alexander Huber.

iotaMotion Announces First Use of its iotaSOFT® Insertion System Outside the United States

iotaMotion, Inc., a pioneer in robotic-assisted systems for cochlear implant surgery, today announced the first use of the iotaSOFT® Insertion System outside of the United States. The technology is currently being applied as part of a pre-market clinical investigation at University Hospital of Zurich, headed by Professor Alexander Huber. This study marks a significant step in expanding access to iotaMotion's innovative technology, which is designed to optimize the precision and safety of cochlear implant surgery.

The iotaSOFT® Insertion System, already commercialized in the United States, offers a unique robotic-assisted approach to inserting electrode arrays used in cochlear implants. The system is designed to provide extremely slow and consistent insertion, which is particularly important for preserving delicate intracochlear structures and enabling optimal positioning of the electrode array. Moreover, the system's advanced capabilities allow for real-time monitoring of ECochG signals, enabling surgeons to make dynamic adjustments to insertion parameters to achieve optimal electrode placement.

"We are thrilled to see the first use of the iotaSOFT® Insertion System outside of the United States at such a prestigious institution as University Hospital of Zurich," stated Mike Lobinsky, President & CEO of iotaMotion. "The team at Zurich has been an exceptional partner, and we look forward to continuing our relationship as we work together to advance cochlear implant care and explore techniques that have never been used in a clinical setting prior to this study."

iotaMotion is committed to expanding the availability of its robotic-assisted systems to surgeons and patients worldwide. The company's mission is to empower surgeons with the tools they need to perform surgery with unmatched precision and control, ultimately leading to better outcomes for patients.

"This collaboration with iotaMotion aligns perfectly with our commitment to pushing the boundaries of hearing health technology and improving the lives of patients with hearing loss," added Professor Huber. "We are honored to be the first center in Europe to introduce this groundbreaking system and contribute to its global launch."

iotaMotion, Inc. is a privately held company headquartered in St. Paul, MN, focused on developing and commercializing robotic-assisted systems for cochlear implant surgery. The company's mission is to revolutionize cochlear implant surgery by harnessing robotic technology to enhance the precision, safety, and effectiveness of surgical procedures.iotaMotion, Inc. is a privately held company headquartered in St. Paul, MN, dedicated to advancing cochlear implant surgery beyond human capability through robotic-assisted solutions. Its flagship technology, the iotaSOFT® Insertion System, is designed to provide a slow and consistent electrode array insertion that is designed to preserve delicate intracochlear structures and optimize the insertion for optimal IV stimulation. The system is commercially available in the United States and currently undergoing a pre-market clinical investigation in other global markets. For more information, visit www.iotamotion.com or contact Wade Colburn, Vice President of Marketing and Clinical, at pr@iotamotion.com.

Disclaimer:info@kdj.com

The information provided is not trading advice. kdj.com does not assume any responsibility for any investments made based on the information provided in this article. Cryptocurrencies are highly volatile and it is highly recommended that you invest with caution after thorough research!

If you believe that the content used on this website infringes your copyright, please contact us immediately (info@kdj.com) and we will delete it promptly.

Other articles published on Jun 19, 2025